Literature DB >> 18715741

Factors affecting willingness to provide buprenorphine treatment.

Julie Netherland1, Michael Botsko, James E Egan, Andrew J Saxon, Chinazo O Cunningham, Ruth Finkelstein, Mark N Gourevitch, John A Renner, Nancy Sohler, Lynn E Sullivan, Linda Weiss, David A Fiellin.   

Abstract

Buprenorphine is an effective long-term opioid agonist treatment. As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices. Although many patients have benefited from the availability of buprenorphine in the United States, almost half of current prescribers are addiction specialists suggesting that buprenorphine treatment has not yet fully penetrated general practice settings. We examined factors affecting willingness to offer buprenorphine treatment among physicians with different levels of prescribing experience. Based on their prescribing practices, physicians were classified as experienced, novice, or as a nonprescriber and asked to assess the extent to which a list of factors impacted their prescription of buprenorphine. Several factors affected willingness to prescribe buprenorphine for all physicians: staff training; access to counseling and alternate treatment; visit time; buprenorphine availability; and pain medications concerns. Compared with other physicians, experienced prescribers were less concerned about induction logistics and access to expert consultation, clinical guidelines, and mental health services. They were more concerned with reimbursement. These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715741      PMCID: PMC2866292          DOI: 10.1016/j.jsat.2008.06.006

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  37 in total

1.  Screening and intervention for illicit drug abuse: a national survey of primary care physicians and psychiatrists.

Authors:  P D Friedmann; D McCullough; R Saitz
Journal:  Arch Intern Med       Date:  2001-01-22

2.  Office-based treatment for opioid dependence: reaching new patient populations.

Authors:  D A Fiellin; R A Rosenheck; T R Kosten
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

3.  Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.

Authors:  H M Rhoades; D Creson; R Elk; J Schmitz; J Grabowski
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

Review 4.  Pharmacologic treatment of heroin-dependent patients.

Authors:  P G O'Connor; D A Fiellin
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  Treatment of heroin dependence with buprenorphine in primary care.

Authors:  David A Fiellin; Michael V Pantalon; Juliana P Pakes; Patrick G O'Connor; Marek Chawarski; Richard S Schottenfeld
Journal:  Am J Drug Alcohol Abuse       Date:  2002       Impact factor: 3.829

6.  Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet.

Authors:  Joseph O Merrill; Lorna A Rhodes; Richard A Deyo; G Alan Marlatt; Katharine A Bradley
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

7.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05

8.  Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs.

Authors:  C Laine; W W Hauck; M N Gourevitch; J Rothman; A Cohen; B J Turner
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

9.  Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years.

Authors:  D M Novick; H Joseph; E A Salsitz; M F Kalin; J B Keefe; E L Miller; B L Richman
Journal:  J Gen Intern Med       Date:  1994-03       Impact factor: 5.128

10.  Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years.

Authors:  J R Robertson; P J Ronald; G M Raab; A J Ross; T Parpia
Journal:  BMJ       Date:  1994-08-06
View more
  65 in total

1.  Improving temporal efficiency of outpatient buprenorphine induction.

Authors:  Erik W Gunderson; Frances R Levin; Margaret M Rombone; Suzanne K Vosburg; Herbert D Kleber
Journal:  Am J Addict       Date:  2011-07-18

2.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

3.  Implementation science for the prevention and treatment of HIV/AIDS.

Authors:  Bruce R Schackman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

4.  Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders.

Authors:  Benjamin R Nordstrom; Elizabeth C Saunders; Bethany McLeman; Andrea Meier; Haiyi Xie; Chantal Lambert-Harris; Beth Tanzman; John Brooklyn; Gregory King; Nels Kloster; Clifton Frederick Lord; William Roberts; Mark P McGovern
Journal:  J Addict Med       Date:  2016 Mar-Apr       Impact factor: 3.702

5.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

6.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

7.  Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.

Authors:  Carrie M Farmer; Dawn Lindsay; Jessica Williams; Amanda Ayers; James Schuster; Alyssa Cilia; Michael T Flaherty; Todd Mandell; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2015-04-06       Impact factor: 3.716

Review 8.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

9.  Expanding treatment for opioid use disorder in publicly funded primary care clinics: Exploratory evaluation of the NYC health + hospitals buprenorphine ECHO program.

Authors:  Babak Tofighi; Noah Isaacs; Hannah Byrnes-Enoch; Rebecca Lakew; Joshua D Lee; Carolyn Berry; Daniel Schatz
Journal:  J Subst Abuse Treat       Date:  2019-08-09

10.  Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.

Authors:  Elizabeth A Evans; Caroline Yoo; David Huang; Andrew J Saxon; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2019-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.